EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity

Yu Wei, Tingwei Zhang, Beihe Wang, Jian Pan iD, Shengming Jin iD, Bangwei Fang iD, Weijie Gu, Xiaojian Qin, Bo Dai, Guowen Lin, Hualei Gan, Junlong Wu iD und 2 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Yu Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, China. Hauptthemen laut MEDLINE: Genomics, Prostatic Neoplasms, East Asian People. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Anti-Cancer Association Foundation, Natural Science Foundation of Shanghai, Program of Shanghai Academic Research Leader.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although there is a well‐known disparity in prostate cancer (PC) incidence and mortality between Chinese and Western patients, the underlying genomic differences have been investigated only sparsely. This clinicogenomic study was conducted to reveal the genomic mutations contributing to the PC disparity across ethnicities and investigate the mutational profile of Chinese PC patients. A total of 1016 Chinese PC patients were prospectively enrolled and subjected to targeted sequencing, resulting in usable sequencing data for 41 genes from 859 patients. Genomic data retrieved from The Cancer Genome Atlas (TCGA; locoregional PC), Memorial Sloan Kettering Cancer Center [MSKCC; metastatic castration‐sensitive PC (mCSPC)], and Stand Up To Cancer [SU2C; metastatic castration‐resistant PC (mCRPC)] cohorts were used as comparators representing Western men. Genomic mutations were analyzed using an integrated bioinformatic strategy. A comparison of the disease stages revealed that mutations in tumor protein 53 ( TP53 ), androgen receptor ( AR ), forkhead box A1 ( FOXA1 ), and genes involved in the cell cycle pathway were enriched in mCRPC. Mutations in adenomatous polyposis coli ( APC ) gene were found to be more prevalent in patients with visceral metastasis. Genomic differences between Western and Chinese men were mainly observed in castration‐sensitive PC, with tumors from Chinese men having more FOXA1 (11.4% vs. 4.2%) but fewer TP53 (4.8% vs. 13%) mutations in locoregional PC and harboring fewer TP53 (11% vs. 29.2%), phosphatase and tensin homolog ( PTEN ; 2.5% vs. 10.3%), and APC (1.7% vs. 7.4%) mutations in the mCSPC stage than those of Western men. Patients of both ethnicities with mCRPC had similar mutational spectra. Furthermore, FOXA1 class‐2 was less common than FOXA1 class‐1 and showed no enrichment in metastasis, contrary to the findings in the Western cohort. Our study provides a valuable resource for a better understanding of PC in China and reveals the genomic alterations associated with PC disparity across races.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GenomicsProstatic NeoplasmsEast Asian PeopleAgedAged, 80 and overHumansMaleMiddle AgedChinaHepatocyte Nuclear Factor 3-alphaMutationProspective StudiesReceptors, AndrogenTumor Suppressor Protein p53Adenomatous Polyposis Coli Protein

Stichwörter der Autor:innen

Chinese populationFOXA1clinical sequencing cohortethnic disparityprostate cancer

Substanzen

FOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaReceptors, AndrogenTP53 protein, humanTumor Suppressor Protein p53APC protein, humanAdenomatous Polyposis Coli Protein

Autor:innen und Institutionen

  • Department of Urology, Fudan University Shanghai Cancer Center, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Shanghai Genitourinary Cancer Institute, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, China.

ORCID-Profile: Jian Pan, Shengming Jin, Bangwei Fang, Junlong Wu, Dingwei Ye, Yao Zhu

Förderung

  • Chinese Anti-Cancer Association Foundation
  • Natural Science Foundation of Shanghai
  • Program of Shanghai Academic Research Leader
  • Shanghai Medical Innovation Research Special Project
  • the General Program of Beijing Xisike Clinical Oncology Research Foundation
  • the National Nature Science Foundation of China
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Wei, Y., Zhang, T., Wang, B., Pan, J., Jin, S., Fang, B., Gu, W., Qin, X., Dai, B., Lin, G., Gan, H., Wu, J., Ye, D., & Zhu, Y. (2023). Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity. Molecular Oncology. https://doi.org/10.1002/1878-0261.13511

Vancouver

Wei Y, Zhang T, Wang B, Pan J, Jin S, Fang B, et al. Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity. Molecular Oncology. 2023. doi:10.1002/1878-0261.13511

BibTeX
@article{Wei2023,
  author = {Wei, Yu and Zhang, Tingwei and Wang, Beihe and Pan, Jian and Jin, Shengming and Fang, Bangwei and Gu, Weijie and Qin, Xiaojian and Dai, Bo and Lin, Guowen and Gan, Hualei and Wu, Junlong and Ye, Dingwei and Zhu, Yao},
  title = {Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13511}
}
Kostenlos starten →